Ask VialBase
review · PMID 19381150

Glucagon receptor agonism in the treatment of obesity and diabetes — VialBase Research

high

Last updated · 2009 · Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D.J., Chaudhary, N. · Nature Reviews Drug Discovery
Key findings
  • Glucagon receptor agonism increases energy expenditure via thermogenesis
  • Stimulates hepatic fat oxidation and reduces liver fat
  • Provides mechanistic rationale for triple agonism in retatrutide

Summary

Review examining the therapeutic potential of glucagon receptor agonism for obesity and metabolic disease. Glucagon’s thermogenic and lipolytic properties, historically considered detrimental (hyperglycemia risk), are reframed as beneficial when combined with GLP-1 and GIP agonism — the approach embodied by retatrutide.

Key Findings

  • Glucagon receptor activation increases energy expenditure through thermogenesis
  • Stimulates hepatic fatty acid oxidation and reduces liver fat content
  • Promotes lipolysis in adipose tissue, mobilizing stored fat
  • Risk of hyperglycemia can be offset by concurrent GLP-1 agonism (as in retatrutide)
  • Glucagon may explain the additional weight loss of triple vs dual agonism
  • Unique metabolic effects beyond appetite suppression (the primary mechanism of GLP-1 RAs)

Methodology

Comprehensive review of glucagon receptor biology, preclinical studies in rodent and primate models, and the pharmacological rationale for multi-receptor agonist approaches in metabolic disease.

Limitations

  • Glucagon’s hyperglycemic effect remains a safety concern requiring mitigation
  • Thermogenic effects may be dose-limiting due to cardiac effects
  • Long-term safety of chronic glucagon receptor agonism unknown
  • Lean mass effects of glucagon need monitoring (could promote muscle catabolism)
  • Review predates retatrutide clinical data — theoretical framework

Relevance to Content

Explains the “third leg” of retatrutide’s mechanism — why adding glucagon to GIP/GLP-1 produces superior results. The thermogenesis and liver fat angles differentiate retatrutide content from semaglutide/tirzepatide content. Important for articles explaining the evolution of incretin therapies and why more receptors may mean better outcomes.

See Also

View on PubMed · PMID 19381150 →